888集团电子游戏(官方VIP认证)-Green Game Store

Whole Exome Sequencing for Genetic Disease
Introduction

Currently, more than 12,000 monogenic diseases have been reported worldwide. According to the statistics of the World Health Organization, the incidence rates of most monogenic diseases are 0.65-1%, and the total incidence rate exceeds 1%. The number of patients with monogenic genetic diseases worldwide has reached up to 20 million. Among them, the patients with severe or intermediate thalassemia number about 0.3 million. The number of carriers with thalassemia variants is up to 30 million. The human exome contains about 180,000 exons from protein-coding genes. Although the exome only accounts for 1% of the whole genome, it is closely related to multiple diseases. By now, 85% of human pathogenic mutations have been found in exons.

Whole exome sequencing can effectively help us clarify the genetic factors of monogenic diseases, deeply explore the internal relationship between diseases and genetic variations, and provide more scientific guidance for carriers and patients’ families.

Advantages
  • COVERAGE AREA
    including all exons with 100bp of flanking sequences from 20,000 protein-coding genes.
  • DETECTION TECHNOLOGY
    Targeted sequence capture and high-throughput sequencing technology
  • VERIFICATION TECHNOLOGY
    Sanger sequencing
  • SEQUENCING DEPTH
    The average sequencing depth exceeds 200×
  • DETECTION PERIOD
    30 workdays
Applicable
  • POPULATION-APPLICABLE: Patients with a specific genetic familial disease history;
  • Patients who have atypical symptoms of diseases, or whose itiology have not been determined through various medical tests;
  • Patients have organ abnormalities accompanied with clinical symptoms of monogenic diseases;
  • Patients with unexplained growth retardation, mental retardation, polyneuropathy and mental disorder.
XML 地图